Top Stories

NVIDIA Corporation (NASDAQ: NVDA) is scheduled to report its second-quarter results after Thursday's close. Analysts, on average, expect EPS of $1.66 on revenue of $3.1 billion. The Analysts BMO Capital Markets' Ambrish Srivastava maintains a Market Perform rating on Nvidia with an...

The Coca-Cola Co (NYSE: KO)'s Powerade may never been able to match up with PepsiCo, Inc (NASDAQ: PEP)'s Gatorade, but Coca-Cola has a new plan to win the sports drink wars. What Happened? Coca-Cola announced Tuesday it has acquired a minority stake in the fast-growing sports...

Casino stocks have taken a beating in recent weeks, and one Wall Street analyst says it’s time for investors to step in and buy the dip in a handful of top stocks. The Analyst Jefferies analyst David Katz updated his ratings and price targets for the following gaming stocks: Upgraded Boyd...

Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) subsidiary Google is the gold standard of internet search and the primary destination for Americans with questions about just about anything. Amazon.com, Inc. (NASDAQ: AMZN) CEO Jeff Bezos is the world’s richest man, so it’s understandable...

Nineteen out of 24 payments and payment processor stocks under JPMorgan's coverage are outperforming the S&P 500 index. Despite strong outperformance, the group remains attractive. The Analyst JPMorgan's Tien-tsin Huang made the following rating changes: Alliance Data Systems...

Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date. What Happened? On this day 83 years ago, the U.S. Social Security Act was signed into law. Where The Market Was The Dow Jones Industrial Average closed at 128.27 and the S&P 500 traded at 11.37....

The Inception Companies, the private investment firm behind Medmen Enterprises Inc (CNSX: MMEN) (OTC: MMNFF) and several other cannabis ventures, announced the launch of the Inception REIT (I-REIT) to provide the cannabis industry with real estate debt and equity capital solutions. REITs, or real...

Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk revealed Monday he is working with two major banks to take Tesla private, and Tesla announced it has created a formal committee to look into whether going private at $420 per share is in the best interest of Tesla stockholders.  What Happened? Elon Musk...

Goldman Sachs zeroed in on the metals and mining space this week after companies in the sector reported quarterly earnings.  The Analyst Analyst Matthew Korn downgraded Kaiser Aluminum Corp. (NASDAQ: KALU) from Neutral to Sell and reduced the 12-month price target from $105 to $101. The...

Data center designer and technology infrastructure company Switch Inc (NYSE: SWCH)'s second-quarter earnings report and disappointing guidance prompted JPMorgan to drop its bullish stance.  The Analyst JPMorgan's Richard Choe downgraded Switch from Overweight to Neutral with a...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 13) Iradimed Corp (NASDAQ: IRMD) SurModics, Inc. (NASDAQ: SRDX) Down In The Dumps (Stocks hitting 52-week lows on Aug. 13) Acasti Pharma (NASDAQ: ACST)...

A recent study from Bankrate revealed that cash is millennials' preferred long-term investment. While cash is certainly the safest bet in the near-term, historical evidence suggests millennials who stick to this investment strategy over time will be missing out on some major wealth. By The...

If there were any lingering doubts about Tiger Woods' popularity, they weren’t evident at the PGA Championship Sunday in St. Louis. The golfing legend may not have won, but he stole the show and virtually of all thunder from eventual winner Brooks Koepka. The Tiger Woods 'halo effect...

Deutsche Bank AG (USA) (NYSE: DB) stock is down nearly 40 percent year-to-date, but one analyst says things are going to get much worse for Deutsche Bank investors before they get better. The Analyst Bank of America analysts led by Andrew Stimpson downgraded Deutsche Bank from Neutral to...

The FDA recently approved Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s patisiran for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. The genetic, often lethal, disease leads to abnormal buildup of amyloid protein in peripheral nerves, heart and other...